Converting Complexities into Successful Therapies with Small Molecule Development!

Small molecules offer incredible potential for treating diseases by effectively reaching intracellular targets and modulating key biological pathways. However, developing these therapies comes with challenges, especially in rapidly evolving conditions like cancer. Our expert scientists are here to provide valuable insights and innovative strategies to help you create powerful, scalable therapies that can truly make a difference.

Small Molecule Development Service by Veeda Lifesciences

Drive your Drug Discovery Forward with Veeda Lifesciences

Preclinical

We play a crucial role in the pharmaceutical pipeline, connecting drug discovery to clinical trials seamlessly. Our team excels in medicinal chemistry, process R&D, and IND/NDA submissions, paving the way for your preclinical success in small molecule development.

line

Clinical Trials

We support you from early-phase safety to late-phase trials, combining deep therapeutic expertise with innovative trial design.

line

BA/BE

With one of the largest healthy volunteer databases and a vast network of hospitals and investigators, we provide comprehensive Bioavailability and Bioequivalence (BA/BE) study services. Our expertise spans study design, sample size determination, trial execution, and advanced statistical methods by focusing on critical factors like drug interchangeability and bioequivalence for highly variable drugs, ensuring the success of your small molecule development.

line

Bioanalytical

Experience the ideal combination of speed and accuracy with our expert researchers. We deliver validated bioanalytical methods for small molecules quickly, helping you accelerate your drug development success.

line

Central Services

Behind every successful small molecule drug is a team that gets the details right. Our central services provide the expertise, integrity, and streamlined processes to turn your small molecule development vision into reality with confidence.

line
line

Frequently Asked Questions

1

We are recognized by leading global regulatory authorities, including the USFDA, WHO, EMA, ANVISA, and regulatory bodies across Europe, including Germany, France, and the Netherlands. Our commitment to rigorous standards and a proven track record of success make us the ideal partner to guide your small molecule development journey.

2

Our extensive library includes bioanalytical methods with over 1,250 assays specifically designed for New Chemical Entities (NCEs), complex molecules, and generics. These methods are designed to meet the analytical requirements of each stage, from discovery through to clinical trials and regulatory submission.

3

We specialize in over 230 complex generic studies, including injectable drugs, inhalation therapies, and 505(b)(2) products. Our extensive experience allows us to handle a wide range of complex drug solutions with expertise and precision.

4

Our facilities and processes undergo regular inspections by global regulatory authorities, including USFDA, EMA, WHO, ANVISA, and several European bodies. We maintain strict compliance with global standards to ensure that your development process meets the highest regulatory requirements.

5

Yes, we offer state-of-the-art bioanalytical support through our in-house laboratories. Equipped with advanced instruments like LCMS, ICP-OES, and SFC MS, we can process up to 1.2 million samples annually, ensuring precision and regulatory compliance for both complex molecules and generics.